CN111246847A - 包含植物营养素和适应原草药的功能性咀嚼胶 - Google Patents
包含植物营养素和适应原草药的功能性咀嚼胶 Download PDFInfo
- Publication number
- CN111246847A CN111246847A CN201880068554.1A CN201880068554A CN111246847A CN 111246847 A CN111246847 A CN 111246847A CN 201880068554 A CN201880068554 A CN 201880068554A CN 111246847 A CN111246847 A CN 111246847A
- Authority
- CN
- China
- Prior art keywords
- chewing gum
- active ingredient
- extract
- vitamin
- piperine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000015218 chewing gum Nutrition 0.000 title claims abstract description 70
- 229940112822 chewing gum Drugs 0.000 title claims abstract description 69
- 235000008216 herbs Nutrition 0.000 title description 11
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims abstract description 47
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims abstract description 47
- 239000004480 active ingredient Substances 0.000 claims abstract description 45
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 claims abstract description 36
- 229940075559 piperine Drugs 0.000 claims abstract description 36
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 claims abstract description 36
- 235000019100 piperine Nutrition 0.000 claims abstract description 36
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 35
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 34
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 31
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 31
- -1 glyceryl phosphatidylcholine Chemical compound 0.000 claims abstract description 30
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 24
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 24
- 230000003340 mental effect Effects 0.000 claims abstract description 24
- 229940110767 coenzyme Q10 Drugs 0.000 claims abstract description 23
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims abstract description 22
- 235000020744 piper nigrum extract Nutrition 0.000 claims abstract description 21
- 229960004441 tyrosine Drugs 0.000 claims abstract description 17
- 229960002173 citrulline Drugs 0.000 claims abstract description 16
- 235000011184 guayusa Nutrition 0.000 claims abstract description 15
- 235000003713 Rhodiola rosea Nutrition 0.000 claims abstract description 14
- 244000042430 Rhodiola rosea Species 0.000 claims abstract description 14
- 235000015418 Bacopa monnieria Nutrition 0.000 claims abstract description 11
- 235000016787 Piper methysticum Nutrition 0.000 claims abstract description 11
- 240000005546 Piper methysticum Species 0.000 claims abstract description 11
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000013477 citrulline Nutrition 0.000 claims abstract description 10
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims abstract description 9
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000001630 malic acid Substances 0.000 claims abstract description 9
- 235000011090 malic acid Nutrition 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 9
- 235000019864 coconut oil Nutrition 0.000 claims abstract description 8
- 239000003240 coconut oil Substances 0.000 claims abstract description 8
- 240000000588 Hericium erinaceus Species 0.000 claims abstract description 6
- 235000007328 Hericium erinaceus Nutrition 0.000 claims abstract description 5
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 5
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 5
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 5
- 229940016667 resveratrol Drugs 0.000 claims abstract description 5
- 244000187129 Bacopa monnieria Species 0.000 claims abstract 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 35
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims description 20
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 18
- 235000019158 vitamin B6 Nutrition 0.000 claims description 18
- 239000011726 vitamin B6 Substances 0.000 claims description 18
- 229940011671 vitamin b6 Drugs 0.000 claims description 18
- 239000000284 extract Substances 0.000 claims description 17
- 241001632410 Eleutherococcus senticosus Species 0.000 claims description 14
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 11
- 244000075850 Avena orientalis Species 0.000 claims description 11
- 235000007319 Avena orientalis Nutrition 0.000 claims description 11
- DATAGRPVKZEWHA-UHFFFAOYSA-N L-gamma-glutamyl-n-ethylamine Natural products CCNC(=O)CCC(N)C(O)=O DATAGRPVKZEWHA-UHFFFAOYSA-N 0.000 claims description 10
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 claims description 10
- 229960000744 vinpocetine Drugs 0.000 claims description 10
- 235000011472 cat’s claw Nutrition 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 241000607122 Uncaria tomentosa Species 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- 239000011777 magnesium Substances 0.000 claims description 6
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 claims description 6
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 claims description 6
- 241000222336 Ganoderma Species 0.000 claims description 5
- 235000011471 Quercus robur Nutrition 0.000 claims description 4
- 240000009089 Quercus robur Species 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- 235000006521 Pleurotus eryngii var ferulae Nutrition 0.000 claims description 3
- 244000088486 Pleurotus eryngii var. ferulae Species 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- 235000001055 magnesium Nutrition 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- 235000013162 Cocos nucifera Nutrition 0.000 claims description 2
- 244000060011 Cocos nucifera Species 0.000 claims description 2
- 229930003779 Vitamin B12 Natural products 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 229940018551 uncaria tomentosa root extract Drugs 0.000 claims description 2
- 235000019163 vitamin B12 Nutrition 0.000 claims description 2
- 239000011715 vitamin B12 Substances 0.000 claims description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims 2
- 241000222350 Pleurotus Species 0.000 claims 2
- 229930003451 Vitamin B1 Natural products 0.000 claims 2
- 229930003571 Vitamin B5 Natural products 0.000 claims 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 2
- 229960002079 calcium pantothenate Drugs 0.000 claims 2
- 229960003495 thiamine Drugs 0.000 claims 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims 2
- 235000010374 vitamin B1 Nutrition 0.000 claims 2
- 239000011691 vitamin B1 Substances 0.000 claims 2
- 239000011675 vitamin B5 Substances 0.000 claims 2
- 235000009492 vitamin B5 Nutrition 0.000 claims 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims 1
- 240000002022 Anthriscus cerefolium Species 0.000 claims 1
- 235000007258 Anthriscus cerefolium Nutrition 0.000 claims 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims 1
- 244000203593 Piper nigrum Species 0.000 claims 1
- 235000008184 Piper nigrum Nutrition 0.000 claims 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims 1
- 241001278833 Rosa laevigata Species 0.000 claims 1
- 235000000661 Rosa laevigata Nutrition 0.000 claims 1
- 229930003471 Vitamin B2 Natural products 0.000 claims 1
- 235000013614 black pepper Nutrition 0.000 claims 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 229940091250 magnesium supplement Drugs 0.000 claims 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims 1
- 229960002477 riboflavin Drugs 0.000 claims 1
- 235000019164 vitamin B2 Nutrition 0.000 claims 1
- 239000011716 vitamin B2 Substances 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 235000016804 zinc Nutrition 0.000 claims 1
- 240000004482 Withania somnifera Species 0.000 description 25
- 235000001978 Withania somnifera Nutrition 0.000 description 23
- 210000004556 brain Anatomy 0.000 description 20
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 16
- SASUFNRGCZMRFD-JCUIILOWSA-N withanolide D Chemical compound C1C(C)=C(C)C(=O)O[C@H]1[C@](C)(O)[C@@H]1[C@@]2(C)CC[C@@H]3[C@@]4(C)C(=O)C=C[C@H](O)[C@@]54O[C@@H]5C[C@H]3[C@@H]2CC1 SASUFNRGCZMRFD-JCUIILOWSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 230000035882 stress Effects 0.000 description 15
- 230000002708 enhancing effect Effects 0.000 description 13
- 238000010521 absorption reaction Methods 0.000 description 12
- 239000003963 antioxidant agent Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 235000006708 antioxidants Nutrition 0.000 description 10
- 230000015654 memory Effects 0.000 description 10
- 239000002858 neurotransmitter agent Substances 0.000 description 10
- 235000015097 nutrients Nutrition 0.000 description 10
- 229960000890 hydrocortisone Drugs 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 229940116257 pepper extract Drugs 0.000 description 8
- PUKLDDOGISCFCP-JSQCKWNTSA-N 21-Deoxycortisone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2=O PUKLDDOGISCFCP-JSQCKWNTSA-N 0.000 description 7
- 240000002999 Bacopa monnieri Species 0.000 description 7
- FCYKAQOGGFGCMD-UHFFFAOYSA-N Fulvic acid Natural products O1C2=CC(O)=C(O)C(C(O)=O)=C2C(=O)C2=C1CC(C)(O)OC2 FCYKAQOGGFGCMD-UHFFFAOYSA-N 0.000 description 7
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 7
- 229960004373 acetylcholine Drugs 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000002509 fulvic acid Substances 0.000 description 7
- 229940095100 fulvic acid Drugs 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 150000003904 phospholipids Chemical class 0.000 description 7
- 239000009405 Ashwagandha Substances 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 210000004958 brain cell Anatomy 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 230000027288 circadian rhythm Effects 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 230000036651 mood Effects 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000001993 wax Substances 0.000 description 6
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 5
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229960001231 choline Drugs 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 5
- 229960003987 melatonin Drugs 0.000 description 5
- 239000003642 reactive oxygen metabolite Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 230000007958 sleep Effects 0.000 description 5
- DBRXOUCRJQVYJQ-CKNDUULBSA-N withaferin A Chemical compound C([C@@H]1[C@H]([C@@H]2[C@]3(CC[C@@H]4[C@@]5(C)C(=O)C=C[C@H](O)[C@@]65O[C@@H]6C[C@H]4[C@@H]3CC2)C)C)C(C)=C(CO)C(=O)O1 DBRXOUCRJQVYJQ-CKNDUULBSA-N 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- 241001489091 Ganoderma sinense Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 235000003434 Sesamum indicum Nutrition 0.000 description 4
- 244000040738 Sesamum orientale Species 0.000 description 4
- 230000036626 alertness Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 4
- 230000002060 circadian Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000013016 learning Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000000116 mitigating effect Effects 0.000 description 4
- 210000000653 nervous system Anatomy 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 240000000599 Lentinula edodes Species 0.000 description 3
- 241001165494 Rhodiola Species 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 230000003920 cognitive function Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000686 essence Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 210000003016 hypothalamus Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 244000099147 Ananas comosus Species 0.000 description 2
- 235000007119 Ananas comosus Nutrition 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 235000014161 Caesalpinia gilliesii Nutrition 0.000 description 2
- 244000003240 Caesalpinia gilliesii Species 0.000 description 2
- 208000017164 Chronobiology disease Diseases 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 244000004281 Eucalyptus maculata Species 0.000 description 2
- 235000016623 Fragaria vesca Nutrition 0.000 description 2
- 240000009088 Fragaria x ananassa Species 0.000 description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000001419 Melatonin receptor Human genes 0.000 description 2
- 108050009605 Melatonin receptor Proteins 0.000 description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 description 2
- 235000014749 Mentha crispa Nutrition 0.000 description 2
- 244000078639 Mentha spicata Species 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000282320 Panthera leo Species 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 240000007651 Rubus glaucus Species 0.000 description 2
- 235000011034 Rubus glaucus Nutrition 0.000 description 2
- 235000009122 Rubus idaeus Nutrition 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- JAVFSUSPBIUPLW-QEWGJZFKSA-N Withanolide Natural products O=C1[C@@H](C)[C@H](C)C[C@H]([C@@H](C)[C@@H]2[C@@]3(C)[C@H]([C@@H]4[C@@H]([C@]5(C)[C@@H](CC4)CCCC5)CC3)CC2)O1 JAVFSUSPBIUPLW-QEWGJZFKSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000008122 artificial sweetener Substances 0.000 description 2
- 235000021311 artificial sweeteners Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000037410 cognitive enhancement Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 239000008123 high-intensity sweetener Substances 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 229920003051 synthetic elastomer Polymers 0.000 description 2
- 230000035924 thermogenesis Effects 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 229960004747 ubidecarenone Drugs 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- PQZVBIJEPVKNOZ-PCLZMVHQSA-N (2R)-2-[(1S)-1-hydroxy-1-[(5R,6R,8R,9S,10R,13S,14R,17S)-5,6,14,17-tetrahydroxy-10,13-dimethyl-1-oxo-6,7,8,9,11,12,15,16-octahydro-4H-cyclopenta[a]phenanthren-17-yl]ethyl]-4,5-dimethyl-2,3-dihydropyran-6-one Chemical class C1C(C)=C(C)C(=O)O[C@H]1[C@](C)(O)[C@@]1(O)[C@@]2(C)CC[C@@H]3[C@@]4(C)C(=O)C=CC[C@]4(O)[C@H](O)C[C@H]3[C@]2(O)CC1 PQZVBIJEPVKNOZ-PCLZMVHQSA-N 0.000 description 1
- NUFKRGBSZPCGQB-FLBSXDLDSA-N (3s)-3-amino-4-oxo-4-[[(2r)-1-oxo-1-[(2,2,4,4-tetramethylthietan-3-yl)amino]propan-2-yl]amino]butanoic acid;pentahydrate Chemical compound O.O.O.O.O.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C NUFKRGBSZPCGQB-FLBSXDLDSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical class OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 239000004377 Alitame Substances 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 235000007558 Avena sp Nutrition 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 244000304217 Brassica oleracea var. gongylodes Species 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000028937 DNA protection Effects 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 206010012209 Delayed sleep phase Diseases 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000008777 Glycerylphosphorylcholine Substances 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241001071918 Heliotropium Species 0.000 description 1
- 244000215562 Heliotropium arborescens Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- 241000226555 Leontopodium Species 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 235000010624 Medicago sativa Nutrition 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 108050004114 Monellin Proteins 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241001465382 Physalis alkekengi Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 235000002634 Solanum Nutrition 0.000 description 1
- 241000207763 Solanum Species 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- ZZWQHNRGJQENEP-KXQOOQHDSA-N [(2r)-2,3-bis[(2-tetradecylsulfanylacetyl)oxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCSCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CSCCCCCCCCCCCCCC ZZWQHNRGJQENEP-KXQOOQHDSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000019409 alitame Nutrition 0.000 description 1
- 108010009985 alitame Proteins 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000037147 athletic performance Effects 0.000 description 1
- 239000002012 ayurvedic medicine Substances 0.000 description 1
- 229920005601 base polymer Polymers 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 230000036995 brain health Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 229940119201 cedar leaf oil Drugs 0.000 description 1
- 239000010627 cedar oil Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000006790 cellular biosynthetic process Effects 0.000 description 1
- 230000010267 cellular communication Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 230000008632 circadian clock Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 231100000876 cognitive deterioration Toxicity 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000002706 dry binder Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- UXAYDBNWIBJTRO-UHFFFAOYSA-N ethenyl acetate;ethenyl dodecanoate Chemical compound CC(=O)OC=C.CCCCCCCCCCCC(=O)OC=C UXAYDBNWIBJTRO-UHFFFAOYSA-N 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000014198 functional gum Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229960004956 glycerylphosphorylcholine Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000006049 herbal material Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000003864 humus Substances 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 230000008799 immune stress Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000006883 memory enhancing effect Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000036997 mental performance Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012169 petroleum derived wax Substances 0.000 description 1
- 235000019381 petroleum wax Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- 125000001474 phenylpropanoid group Chemical group 0.000 description 1
- 238000009160 phytotherapy Methods 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QWDDFCKIEJCEMF-UHFFFAOYSA-N propane-1,2,3-triol 2-(trimethylazaniumyl)ethyl hydrogen phosphate Chemical compound OCC(O)CO.C[N+](C)(C)CCOP(O)([O-])=O QWDDFCKIEJCEMF-UHFFFAOYSA-N 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 150000004059 quinone derivatives Chemical class 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 230000008454 sleep-wake cycle Effects 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 210000000221 suprachiasmatic nucleus Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 239000001789 thuja occidentalis l. leaf oil Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical group COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/49—Fagaceae (Beech family), e.g. oak or chestnut
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及一种包含胶基和活性成分的功能性咀嚼胶，所述活性成分增强精神清晰度和集中力，其中所述活性成分选自喜来芝、南非醉茄、辅酶Q10、L‑酪氨酸、红景天、假马齿苋、L‑α甘油基磷脂酰胆碱(α‑GPC)、Guayusa、磷脂酰丝氨酸(优选地，无GMO)和胡椒碱(即黑胡椒提取物)。本发明还涉及一种缓解疲劳和增强能量的包含胶基和活性成分的功能性咀嚼胶，其中所述活性成分选自喜来芝、辅酶Q10、瓜氨酸苹果酸、刺五加、L‑酪氨酸、灵芝(Reishi)、猴头菇(狮鬃菇)、椰油粉、喜来芝、Guayusa、白藜芦醇和胡椒碱(黑胡椒提取物)。
Description
发明领域
本发明涉及保健营养品领域，特别是涉及包含植物营养素和适应原草药的功能性咀嚼胶。本发明的咀嚼胶包含胶基以及植物营养素和适应原草药的平衡混合物，其以协同方式增强精神清晰度和集中力和/或疲劳缓解和能量增强，和/或充当昼夜节律调节器以帮助抵消神经递质失衡，从而改善情绪、精神清晰度和身体耐力。
发明背景
昼夜节律紊乱已被证实对健康受试者的许多生物系统产生负面影响，尤其是；免疫、炎症和氧化应激系统。已经提出了多种机制来解释睡眠和氧化应激之间的相关性，包括参与外周组织中氧化应激的基因的转录应答中的与睡眠相关的变化。然而，还没有公开用于昼夜节律障碍的许多医学治疗方法。
有多种昼夜节律转录因子可控制细胞中的正反馈和负反馈回路，以确定关键器官和系统(包括心、肺、免疫系统和新陈代谢)以及细胞内过程(例如细胞呼吸和DNA修复)的功能。这种内部时钟系统调节人体整个基因活动的大约三分之一！调节这些系统的遗传密码会影响人体达到最佳性能的时机，例如您是早起的人还是夜猫子。
您昼夜节律的中央调节器是视交叉上核SCN，其可在大脑的下丘脑中发现。它主要通过控制褪黑素的分泌来实现这点，褪黑素是主要的昼夜节律激素。昼夜节律紊乱也会降低预期寿命。此外，随着个体年龄增长，人们对昼夜节律的破坏变得更加敏感，而对同步技术则变得不那么敏感。
最近的研究表明，抑郁症患者的SCN中的褪黑素受体数量增加。褪黑素受体的增加可能是情绪障碍患者褪黑素水平降低的补偿机制，最近已建议将这些受体作为新型抗抑郁药的靶标。
褪黑素除具有控制昼夜节律的作用外，还具有抗氧化特性，可作为电子供体清除自由基以保护脂质、蛋白质和DNA免受氧化损伤。当氧化剂-抗氧化剂平衡失调时，由于活性氧物质(ROS)过量产生和/或抗氧化剂防御能力不足，就会发生氧化损伤。褪黑素比其他细胞内抗氧化剂如谷胱甘肽(GSH)更有效地中和ROS，还可以刺激抗氧化酶的活性。
喜来芝(Shilajit)是阿育吠陀草药医学(ayurvedic medicine)的重要的已知组成部分，这是因为其作为rasayana的特性。在这种情况下，诸如延长寿命、恢复和延缓衰老作用的健康利益可归功于它。这种被称为喜来芝的植物复合物(phytocomplex)主要由腐殖质组成。其中的一员，富里酸，以其诸如抗氧化剂、抗炎和记忆增强剂的特性而为人所知。新的研究表明，富里酸是体外tau蛋白的抗聚集因子，这使得富里酸表现为潜在的抗阿尔茨海默病分子。喜来芝是一种古老的草药，含有超过85种人体以最佳状态工作所需的矿物质和微量元素，并且富里酸可在细胞水平上作为这些矿物质的维生素吸收的催化剂。
南非醉茄(Ashwagandha)和红景天(Rhodiola rosea)是用于压力管理和解决其他健康疾病的草药。虽然它们有一些相似之处，但每种草药都有其独特的特性。南非醉茄已被用于增强能量、记忆力和耐力，以及减轻压力、虚弱、失眠、关节炎、哮喘、免疫力低下、性困难和不育症。
南非醉茄包含活性化合物醉茄内酯(withanolides)，这可解释其治疗活性，尤其涉及炎症、免疫力、记忆力和压力。
红景天，其可以使神经系统恢复活力、增强工作表现、抵抗疲劳、减轻压力、减少抑郁症并增强生育能力。UMHS将红景天的药用特性归因于其类苯基丙烷、苯乙醇衍生物、类黄酮、单萜、三萜和酚酸。
美国专利8,636,985公开了包含南非醉茄草药和L-茶氨酸的营养胶。
本发明提供了一种咀嚼胶，其具有植物营养素和适应原草药的平衡混合物。本发明还提供了一种咀嚼胶，其提供疲劳恢复和额外的能量。
具体实施方案
如本文所用，术语"咀嚼胶"表示任何咀嚼胶，诸如块状或棒状咀嚼胶，夹心咀嚼胶，或压缩咀嚼胶。
术语"胶基"表示通常在添加咀嚼胶的主体部分之前混合在一起的主要不溶于水和疏水性的胶基成分。“胶基”可以包含胶基聚合物和增塑剂、蜡、乳化剂、脂肪和/或填充剂。胶基因此可以表示典型的水不溶性咀嚼胶组分，其可以在第一步中制造，然后在第二步中与用于本发明中的植物营养素混合。
植物营养素、适应原草药和适合用于本发明的功能性咀嚼胶的其他物质优选为以下：
喜来芝，一种古老的草药物质，含有超过85种人体以最佳状态工作所需的矿物质和微量元素以及可在细胞水平上作为这些矿物质的维生素吸收的催化剂的富里酸。
喜来芝的活性成分包括二苯并-α-吡喃酮类和相关代谢产物、小分子肽(构成非蛋白质氨基酸)、一些脂质和载体分子(富里酸)。
此外，已经假设二苯并-α-吡喃酮参与线粒体内的电子传输，从而促进了更多ATP的产生，导致能量增加。因此，发现喜来芝可以增加能量以及其他有益的品质。喜来芝配方中存在的其他分子是eldagic acid、某些脂肪酸、树脂、乳胶、树胶、白蛋白、三萜、固醇、芳香族羧酸、3,4-苯并香豆素、氨基酸、多酚和酚类脂质。
喜来芝在分子水平上刺激皮肤细胞的生长过程。它提高了血液携带氧和铁的能力。喜来芝的这些特性赋予人们健康的外观和青春的光泽。同样，喜来芝的矿物质有助于维持人体最佳的能量代谢速率，该速率随着年龄的增长自然会降低。这点部分是通过平衡电解质水平和燃烧掉多余的脂肪来实现的。阿育吠陀(Ayurveda)从业者兜售其平衡荷尔蒙水平的能力，随着我们年龄的增长，荷尔蒙水平会改变和引起压力。
喜来芝在阿育吠陀(Ayurveda)中广泛使用，可用于多种临床疾病。几个世纪以来，居住在喜马拉雅山及周边地区偏远村庄的人们单独使用喜来芝，或与其他植物疗法联合使用，以预防和与糖尿病作斗争(Tiwari,V.P.,等人,“An interpretation of Ayurvedicafindings on Shilajit,”J.Res.Indigenous Med.(1973)8:57)。此外，作为一种抗氧化剂，其可防止细胞毒性氧自由基对胰细胞的损害(Bhattacharya S.K.,“Shilajit attenuatesstreptozotocin induced diabetes mellitus和decrease in pancreatic isletsuperoxide dismutase activity in rats,”Phytother.Res.(1995)9:41-4；Bhattacharya S.K.,“Effects of Shilajit on biogenic free radicals,”Phytother.Res.(1995)9:56-9；和Ghosal,S.,等人,“Interaction of Shilajit withbiogenic free radicals,”Indian J.Chem.(1995)34B:596-602)。已提出，糖尿病期间的葡萄糖、脂肪和蛋白质代谢的紊乱会导致高脂血症的发展。在一项研究中，喜来芝对大鼠的脂质分布具有显著的有益作用(Trivedi N.A.,等人,“Effect of Shilajit on bloodglucose和lipid profile in alloxan-induced diabetic rats,”Indian J.Pharmacol.(2004)36(6):373-376)。
如所讨论的，喜来芝已被用于治疗各种疾病。还建议将其用作性能增强剂。据报道，富里酸(FAs)在植物、动物以及人类的生理系统中引起许多重要作用，包括：提高矿物质和营养素的生物可利用度，用作电解质，对包括重金属在内的有毒物质进行解毒，用作抗氧化剂，和改善免疫功能。
具有400-2500mg胶基的本发明的胶中的喜来芝的优选量中为50–400mg。
南非醉茄(Withania somnifera,Physalis somnifera)也称为酸浆或印度人参(Indian ginseng)，其既是补品又是镇静剂，这可归因于其适应原性。Withania是指植物主要提取物，并且somifera的字面意思是“诱导睡眠”。根据Sushruta的说法，rasayanas是延缓衰老过程、增加寿命并且增强精神和身体强度的物质。文献记录的使用南非醉茄的潜在利益令人印象深刻。已发表的研究结果和详细益处(诸如安定)有益于失眠，消化紊乱，便秘，和焦虑症。其在镇定的同时强化，给予能量同时还解决神经系统的问题。
南非醉茄增强大脑和神经系统的功能，并改善记忆力。它改善生殖系统的功能，促进健康的性和生殖平衡。作为强大的适应原，它可以增强人体抵抗压力的能力。南非醉茄通过提高细胞介导的免疫力来改善人体对疾病的防御能力。它还具有有效的抗氧化特性，有助于防止自由基造成的细胞损伤。适应原是帮助抵抗压力的草药。压力是精神或情感紧张，如果其随时间推移经常地引发，则可能导致严重的失衡或疾病。适应原还可以改善人体的机能和耐力。
具有400-2500mg胶基的本发明的胶中的南非醉茄的优选量为25–500mg。
辅酶Q10(CoQ10)也称为泛醌或泛癸烯酮，是一种强大的、内源性产生的、细胞内存在的亲脂性抗氧化剂。它与已知与多种人类病理状况有关的活性氧物质(ROS)战斗。其靶点是每个细胞的内线粒体膜(IMM)。辅酶Q10(CoQ10)也称为泛醌或泛癸烯酮，是一种天然的脂溶性、类维生素的、普遍存在的苯醌衍生物。在众所周知的氧化磷酸化过程中，它主要用作抗氧化剂、膜稳定剂和三磷酸腺苷(ATP)产生中的辅因子。通过这种重要作用，它指导细胞机制和合成。靶向神经系统疾病中的细胞能量产生。
具有400-2500mg胶基的本发明的胶中的辅酶Q10的优选量是15–400mg。
磷脂酰丝氨酸(PS)是一种在人类神经组织中高度流行的氨基酸衍生物。这种脂溶性磷脂可见于您身体的每个单个细胞膜中，并且其高度集中在大脑中。磷脂酰丝氨酸对大脑的细胞功能特别重要。磷脂酰丝氨酸不是一种神经递质，而是一种特殊形式的磷脂，它支持改善认知功能、清除抑郁症并增强记忆力和情绪的许多神经递质，磷脂酰丝氨酸(PS)抑制皮质醇，并帮助我们应对压力。
磷脂酰丝氨酸具有独特的结构，使其既具有亲水性(表示其被水吸引)也具有疏水性，或者被水排斥。通过这种结构，磷脂能将它们自己排列成磷脂双层-形成人体细胞膜主要成分的两个平行层。在脑细胞膜中，磷脂双层起着“守门人”的作用，调节进入的有益物质，基本上是营养物质，水和氧气，同时消除了代谢废物。乙酰胆碱的合成需要磷脂酰丝氨酸。
磷脂酰丝氨酸最著名的益处是其改善脑功能的潜力。这种营养物对于保持脑细胞健康和以最佳状态工作是重要的。这对帮助神经元传导神经冲动，支持大脑修复现有脑细胞的能力，产生新的脑细胞以及增加脑细胞的流动性也很重要，因此它们可以有效地应对压力。由于这些对大脑的影响，据信PS可以产生以下大脑健康益处。增强记忆和认知功能。一项研究发现，在一群健康的成年人中，补充磷脂酰丝氨酸有助于将短期记忆中的计算速度提高20％。
除葡萄糖介导外，磷脂酰丝氨酸还可平衡皮质醇水平。肾上腺以昼夜节律的方式产生皮质醇：该激素应在早晨达到峰值，然后逐渐减少，直至晚上。当我们的皮质醇水平不符合这种模式时，身体就会失去平衡。慢性应激水平导致肾上腺排出大量皮质醇，然后使大脑中被称为下丘脑和海马的两部分失敏。磷脂酰丝氨酸不是通过抑制生产，而是通过使下丘脑和海马对该激素重新敏感来重新平衡高水平的皮质醇。
磷脂酰丝氨酸也显示出增强运动表现的潜力。例如，可能会延长运动的人变得疲倦的时间。如多项研究所示，它还减少了运动引起的荷尔蒙不良反应。它还有助于人身伤害的恢复，并且可以帮助人从血流量减少中恢复。
研究证实了磷脂酰丝氨酸对于阿尔茨海默病的潜力，阿尔茨海默病是一种目前已影响超过500万美国人的疾病，其已成为当今该国第六大死亡原因。阿尔茨海默病会促使大脑使用葡萄糖的效率降低，而磷脂酰丝氨酸也可能为其带来益处-它实际上有助于改善受这种情况影响的大脑的葡萄糖代谢。
磷脂-鸡蛋和大豆是其主要的食物来源。药物必须能够穿过细胞膜，以促进其从人体吸收、分布和清除。由于其两亲性特质，磷脂系统与细胞膜相容。脂质乳液系统具有作为药物载体的有吸引力的特性，因为其具有生物可降解性、生物相容性、稳定性和易生产性。
L-α甘油磷酸胆碱(α GPC)。αGPC是在大脑中发现的天然胆碱化合物。它也是拟交感神经药乙酰胆碱的前体，可能具有治疗阿尔茨海默病和其他痴呆症的潜力。α-GPC跨越血脑屏障将胆碱迅速递送至大脑，并且是乙酰胆碱的生物合成前体。
口服α-GPC可导致δ波(通常与深度睡眠有关，并在衰老或认知加速恶化时增加)显著减少和β波(正常醒来意识)显著增加。认知增强作用可能与α-GPC对脑乙酰胆碱(一种神经递质，其增加生长激素释放)释放的刺激作用相关。乙酰胆碱已显示出在标准持续注意任务开始时增加。
控制良好的临床试验报告了甘油磷酸胆碱可改善年轻人的注意力和单词回忆，改善认知能力，记忆力减退者的情绪和行为，有助于脑部创伤的恢复，可用于促进生长激素和可部分恢复衰老的大脑。α-GPC还支持其他递质系统，例如多巴胺、去甲肾上腺素和γ-氨基丁酸(GABA)(体外和体内证据)。
西伯利亚人参(Siberian Ginseng)，刺五加(eleuthero)，一种小型木本灌木，原产于东北亚的高山森林。其在中国和俄罗斯已经使用了数百年，用于预防感冒和流感，增加能量、活力和寿命。在体外和动物模型中均显示出其增加耐力、肌肉力量、增加记忆力和学习力、抗疲劳、增加免疫力和抗抑郁作用。
具有400-2500mg胶基的本发明的胶中的刺五加的优选量是30–200mg。
据信，西伯利亚人参的适应原特性可归因于其对下丘脑-垂体-肾上腺轴的影响，导致血浆促肾上腺皮质激素和皮质类固醇水平升高。通过对于耐受不利条件(热、噪声、运动、工作负荷增加和运动)以改善听觉紊乱、精神警觉度、智力工作能力、工作量、工作质量和运动表现的人类研究的全面回顾，得出的结论认为上述作用的证据是广泛存在的。
对于南非醉茄和红景天来说，根都是用来做药的。这两种草药都被草药专家用来对抗压力和疲劳、支持神经系统、增强耐力和解决不育症。在科学研究领域，南非醉茄最强大的治疗能力在于减轻关节炎的疼痛和肿胀以及支持免疫系统功能。红景天的突出科学功能是增强人体对压力的抵抗力、增强身体耐力、减轻疲劳和焦虑。除了主要的药用用途外，南非醉茄和红景天还具有独特的治疗差异，因此，它们合在一起具有令人难以置信的“协同作用”，使您全天保持镇定，专注和非常可控的能量。
下面列出了对认知增强和快速学习能力有重大影响的其他物质。
磷脂酰丝氨酸可以减缓甚至逆转与中年和老年受试者中痴呆相关的学习、情绪、记忆、集中力、单词回忆的下降或与年龄相关的认知障碍。磷脂酰丝氨酸是一种天然营养素，已被发现能阻止皮质醇的有害作用。磷脂酰丝氨酸不是一种神经递质，而是一种特殊形式的磷脂，它支持改善认知功能、清除抑郁症并增强记忆力和情绪的许多神经递质，磷脂酰丝氨酸(PS)抑制皮质醇，并帮助我们应对压力。磷脂酰丝氨酸对细胞通讯和许多重要任务的编排也重要。其包括刺激许多脑神经递质的释放，调节葡萄糖的利用率，以及激活营养物质向用作看门人(gate-keeper)类型的细胞中的运输。为了使我们的大脑有效学习，它需要适当水平的磷脂酰丝氨酸。FDA认证的健康声明指出，磷脂酰丝氨酸可以减少痴呆和认知功能障碍的风险。
因此，磷脂酰丝氨酸是绝对重要的。衰老将磷脂酰丝氨酸的产生减慢至次优水平，从而使我们无法发挥最大的智力。
对于记忆形成和学习，最重要的大脑化学物质之一称为乙酰胆碱。这种神经递质来自被称为胆碱的前体，并且αGPC是这种必需营养素的主要来源。海马利用乙酰胆碱创造记忆。GPC可以修复和维护细胞，从而使神经元更好、更快地交流。因此，αGPC改善情绪，增强精神能量。多余的胆碱可以提高机敏性和思想清晰度。αGPC因其改善记忆力而倍受赞誉。它的高生物可利用度使其成为生产神经递质乙酰胆碱的胆碱的重要来源。αGPC促进了新的脑细胞的发育。并且增强了大脑修复受损细胞膜的能力。
L-酪氨酸，-是最重要的氨基酸之一，用于合成结构蛋白。酪氨酸对大脑非常有用，因为它是神经递质，可激活大脑中的肾上腺素、多巴胺和血清素，并增强提高机敏性和意识的去甲肾上腺素的比例，以及增加在压力下减少血液供应的肾上腺素(epiphrine)的产生。其他人认为只有在运动产生足够的认知压力和消耗多巴胺或去甲肾上腺素水平的情况下酪氨酸才可以改善身体机能，这是在有压力的条件下(诸如竞争)假设的。
狮鬃菇(Lion’s Mane mushroom)在大脑和整个身体中均具有神经再生能力并增强神经生长。狮鬃菇提取物在活跃期结束时降低了小鼠的清醒度。此外，狮鬃菇的某些成分可以延长睡眠-觉醒周期。因此，已显示狮鬃菇在如痴呆症、阿尔茨海默病和延迟睡眠相障碍等昼夜节律钟损伤中有帮助。
灵芝(Reishi)-灵芝菇(灵芝(Ganoderma lucidum))是一种可食用的药用真菌，已有数千年的历史，可用于多种治疗，是真正的“超级食品”。这些蘑菇在中文中也称为LingZhi(灵芝)，具有很强的抗炎作用，并与长寿、更好的免疫功能和精神抵抗力相关联-也许这就是为什么他们采用了“蘑菇之王”的绰号。
如书籍“Herbal Medicine:Biomolecular and Clinical Aspects”所述，灵芝菇的中文名称代表着“精神力量和永恒精髓的结合……与成功、福祉、神力和长寿息息相关。在种植蘑菇中，灵芝的独特之处在于其重要的是药用价值而非营养价值。”
在包括传统中药(TCM)在内的整体医学实践的整个历史中，灵芝菇被认为是一种适应原性草药样物质，这意味着它们可帮助我们应对压力的负面影响，例如炎症加剧，能量水平耗尽，血液受损血管和各种类型的荷尔蒙失调。研究反复表明，灵芝菇具有抗氧化能力，可以增强人体对癌症、自身免疫性疾病、心脏病、过敏、感染等的防御能力。
燕麦提取物–它具有“启动睡眠”的能力，不仅可以让您有更长的睡眠时间(L-茶氨酸)，而且还可以发挥褪黑素和L-色氨酸的巨大作用(影响血清素)，这对于完整的“昼夜节律”非常重要。偏离您身体的昼夜节律会导致神经系统和生理问题.
猫爪草(Cat’s Claw)增强色氨酸水平，该色氨酸水平可增加血清素并且可以提供镇定作用。
胡椒碱(黑胡椒提取物)(也称为胡椒素TM)具有重要作用，这可归因于其具有增加其他营养化合物生物可利用度的能力。在人体中在细胞水平上产生能量的代谢过程称为生热作用。尽管生热作用被认为是维持体重减轻的关键因素，但它也被认为在利用人体消耗的日常食物和营养中起着不可或缺的作用。
具有400-2500mg胶基的本发明的胶中的胡椒碱的优选量是2–30mg。
植物营养素和适应原草药的协同作用
研究人员表明，一种名为喜来芝的营养丰富的生物质可以提高辅酶Q10的效率。喜来芝因其将能量和营养带入体内的能力而倍受赞誉。当辅酶Q10和喜来芝结合使用时，科学家发现线粒体功能得到改善，线粒体将食物转化为能量的能力增强，组织可利用的能量增加。辅酶Q10提供了一种有效的方法来帮助延缓甚至逆转自然衰老过程。恢复年轻的线粒体针对自由基的保护。辅酶Q10可在体内快速消耗，因为它会提供自己的电子来中和大量的自由基。这使得确保人体持续供应辅酶Q10十分关键，并且已经发现喜来芝将辅酶Q10稳定、活化和保存为其活性(泛醇)形式，从而提高了对于防止线粒体衰老至关重要的辅酶Q10的水平。关键发现是这两种营养素的组合具有协同效应，与单独使用任何一种营养素相比，产生的ATP回收率更高。实际上，喜来芝/CoQ10组合在大脑和血液中使ATP水平几乎回到未运动对照动物的水平！另外一个好处是，喜来芝的添加可以防止血液中辅酶Q10水平的大幅下降。最终，喜来芝和辅酶Q10的协同作用为保护线粒体DNA和抗衰老提供了无与伦比的选择。
植物营养素和适应原草药的生物可利用度
药物的口服吸收是非常重要的问题，尤其是当药物的生物可利用度差、长期服用且价格昂贵时。生物可利用度差的药物仍不能保持亚治疗效果，因为大部分剂量从未达到血浆或发挥药理作用，除非和直到给予非常大的剂量，这也可能导致严重的副作用。生物可利用度的任何显著改善将导致降低该特定药物的剂量或剂量频率。生物增强剂或生物可利用度增强剂大多是基于植物的分子，它们在联合治疗中促进生物活性或生物可利用度或药物的吸收。药物配方的性质可以直接影响其溶解、口服给药后的吸收速率和吸收程度。已对咀嚼胶配方的几种药物进行了评估，包括阿司匹林、维拉帕米和最近使用的尼古丁。咀嚼胶配方相对于片剂或液体制剂具有几个优点，例如：通过咀嚼从咀嚼胶释放的大多数药物被认为是通过颊腔吸收的。由于其广泛的血管形成，特别是对于低分子量疏水剂，认为通过颊腔吸收更快。由于在大多数情况下药物作用的开始取决于递送速度，因此更快的吸收会导致动态反应的持续时间缩短。通过颊腔吸收的药物会绕过肠道和肝脏的首过代谢，这可能会增加其吸收程度。
在本发明中，通过提供包含胡椒碱的功能性胶配方解决了活性成分喜来芝、南非醉茄、辅酶Q10和西伯利亚人参的生物可利用度问题。借助于胡椒碱和通过咀嚼胶提供的颊腔吸收，活性成分的效果出乎意料的迅速和有力，并且由于咀嚼胶具有缓释性能，效果也很持久。
在一个实施方案中，增强精神清晰度和集中力的咀嚼胶的活性成分选自：
喜来芝、L-酪氨酸、L-茶氨酸、维生素B6、维生素B12、猫爪草根提取物(绒毛钩藤(Uncaria tomentosa))、L-α甘油基磷脂酰胆碱(α-GPC)、假马齿苋(Bacopa monnieri)、南非醉茄(Withania somnifera)、狮鬃菇、L-瓜氨酸、长春西汀、胡椒碱(黑胡椒提取物)、叶酸、燕麦提取物(燕麦)、白藜芦醇、紫檀芪、磷脂酰丝氨酸(优选地，无GMO)和红景天。
在优选实施方案中，增强精神清晰度和集中力的咀嚼胶的活性成分选自下组：
-喜来芝、南非醉茄、辅酶Q10、磷脂酰丝氨酸(优选地，无GMO)、L-α甘油基磷脂酰胆碱(α-GPC)和胡椒碱(黑胡椒提取物)；或
-喜来芝、南非醉茄、辅酶Q10、磷脂酰丝氨酸(优选地，无GMO)、假马齿苋和胡椒碱(黑胡椒提取物)。
在一个实施方案中，提供疲劳缓解和能量增强的咀嚼胶的活性成分选自：
喜来芝、辅酶Q10、磷脂酰丝氨酸、甘油基磷脂酰胆碱(αGPC)、西伯利亚人参、灵芝(Reishi)、猴头菇(狮鬃菇)、维生素C、维生素B6、胡椒碱(黑胡椒提取物)，
在优选实施方案中，提供疲劳缓解和能量增强的咀嚼胶的活性成分选自下组：
-喜来芝、辅酶Q10、磷脂酰丝氨酸、甘油基磷脂酰胆碱(αGPC)、西伯利亚人参、灵芝(Reishi)、猴头菇(狮鬃菇)和胡椒碱(黑胡椒提取物)；或
-喜来芝、辅酶Q10、磷脂酰丝氨酸、甘油基磷脂酰胆碱(αGPC)、西伯利亚人参和胡椒碱(黑胡椒提取物)
在另一实施方案中，增强精神清晰度和集中力的咀嚼胶的活性成分选自：L-酪氨酸、L-茶氨酸、燕麦提取物(燕麦(Avena sativa))、磷脂酰丝氨酸、维生素B6、猫爪草根提取物(绒毛钩藤)、L-α甘油基磷脂酰胆碱(α-GPC)、Guayusa、假马齿苋、南非醉茄(Withaniasomnifera)、狮鬃菇、L-瓜氨酸、长春西汀、胡椒碱(黑胡椒提取物)、紫檀芪、磷脂酰丝氨酸(优选地，无GMO)和红景天。
在优选实施方案中，增强精神清晰度和集中力的咀嚼胶的活性成分选自下组：
-南非醉茄、红景天、Guayusa、磷脂酰丝氨酸(优选地，无GMO)和胡椒碱(黑胡椒提取物)；或
-南非醉茄、红景天、L-茶氨酸、胡椒碱(黑胡椒提取物)和L-α甘油基磷脂酰胆碱(α-GPC)。
在另一实施方案中，提供疲劳缓解和能量增强的咀嚼胶的活性成分选自：瓜氨酸苹果酸(citrulline malate)、L-酪氨酸、α-甘油基磷脂酰胆碱、夏栎木提取物"QR"、椰油粉、喜来芝、guayusa、长春西汀、维生素B6、胡椒碱(黑胡椒提取物)、CoQ10、狮鬃菇和灵芝。
在优选实施方案中，提供疲劳缓解和能量增强的咀嚼胶的活性成分选自下组：
-瓜氨酸苹果酸、L-酪氨酸、椰油粉、喜来芝、Guayusa和胡椒碱(黑胡椒提取物)；或
-瓜氨酸苹果酸、α-甘油基磷脂酰胆碱、椰油粉、喜来芝、Guayusa、胡椒碱(黑胡椒提取物)
在优选实施方案中，本发明的功能性咀嚼胶还可包含增强精神清晰度和集中力和/或提供疲劳缓解和能量增强的其他活性成分。
最终咀嚼胶中的胶基的优选量为在任何任选施加的包衣之前的咀嚼胶重量的30-75％，诸如咀嚼胶重量的35-70％，或咀嚼胶重量的40-65％，或咀嚼胶重量的45-60％。
胶基的配方可取决于要制备的具体产品而不同。
胶基可任选包含合成弹性体，诸如聚醋酸乙烯酯或月桂酸乙烯酯-醋酸乙烯酯或其共聚物。
其他合成弹性体可选自下组：苯乙烯-丁二烯共聚物、聚异丁烯、异丁烯-异戊二烯共聚物、聚氨酯和聚乙烯。
胶基可进一步包含：0至40wt％的蜡，5至35wt％的非蜡软化剂(诸如增塑剂、脂肪和乳化剂)，0至50wt％的填充剂，和0至5wt％的其他成分(如抗氧化剂、着色剂等)。在本发明的一个实施方案中，功能性咀嚼胶包含选自下组的其他咀嚼胶成分：调味剂、干粘合剂、压片助剂、抗结块剂、乳化剂、抗氧化剂、增强剂、吸收促进剂、高强度甜味剂、软化剂、色素、活性成分、水溶性不消化性多糖、水不溶性多糖或其任意组合。
在本发明的一个实施方案中，咀嚼胶包含调味剂。调味剂通常可以如下量存在：咀嚼胶重量的0.01％至10％之间，诸如咀嚼胶重量的0.01％至5％。
适用于本发明实施方案中的调味剂的非穷举示例是椰子、咖啡、巧克力、香草、葡萄果、橙子、酸橙、薄荷脑、甘草、焦糖香气、蜂蜜香气、菠萝、草莓、覆盆子、热带水果、樱桃、肉桂、薄荷、冬青、留兰香、桉树和薄荷，选自苹果、梨、桃、草莓、杏、树莓、樱桃、菠萝和李子香精的水果香精。香精油包括薄荷、留兰香、薄荷醇、桉树、茴香、雪松叶油和上述水果的油。
石油蜡有助于固化由胶基制成的成品咀嚼胶，并改善保质期和质地。蜡的晶体大小影响香味的释放。蜡和脂肪通常还用于调节质地和用于在制备咀嚼胶基时软化咀嚼胶基。
抗氧化剂可延长胶基、成品咀嚼胶或它们各自的成分(包括脂肪和香精油)的货架寿命和存储。适用于胶基的抗氧化剂包括丁基化羟基茴香醚、丁基化羟基甲苯、β-胡萝卜素、生育酚、酸化剂(如维生素C)、没食子酸丙酯、其他合成和天然类型或它们的混合物。
根据本发明可以包含在功能性咀嚼胶中的其他咀嚼胶成分包括表面活性剂和/或增溶剂。
在一些实施方案中，一种或多种色素可以包含在咀嚼胶中。
根据本发明的优选实施方案，也可以使用高强度的人造甜味剂。优选的高强度甜味剂包括但不限于单独或组合使用的三氯蔗糖(sucralose)、阿斯巴甜、安赛蜜盐、阿来甜、糖精及其盐、环拉酸及其盐、甘草甜素、二氢查耳酮、奇异果甜蛋白、莫奈林、甜菊糖苷等。
为了提供更长久的甜味和香味感知，可能需要封装或控制至少一部分人造甜味剂的释放。
可以使用湿法制粒、蜡制粒、喷雾干燥、喷雾冷却、流化床包衣、保存、包封在酵母细胞中和纤维挤出的技术来实现所需的释放特性。甜味剂的包封也可以使用另一种咀嚼胶组分或树脂状化合物来提供。
糖和/或非糖甜味剂的组合可以用于咀嚼胶中。
如果需要，咀嚼胶和/或胶基可以包括一种或多种填充剂/纹理剂、包括例如碳酸镁和碳酸钙、硫酸钠、磨碎的石灰石、硅酸盐化合物、镁和硅酸铝、高岭土和粘土、氧化铝、氧化硅、滑石粉、氧化钛、磷酸一、二和三钙、纤维素聚合物(如木材)和它们的组合。
在以下实验部分中进一步描述了本发明，其并非旨在限制本发明的范围。
实施例
实施例1
增强精神清晰度和集中力的咀嚼胶的成分
400-1000mg胶基
500mg南非醉茄
300mg红景天
200mg Guayusa
300mg磷脂酰丝氨酸，无GMO
10mg胡椒素(胡椒碱-黑胡椒提取物)
活性成分的mg水平为相当于每天4颗胶的每日剂量。例如，500mg南非醉茄等于125mg/份胶等。
实施例2
增强精神清晰度和集中力的咀嚼胶的成分
400-1000mg胶基
500mg南非醉茄
300mg红景天
200mg L-茶氨酸
10mg胡椒素(胡椒碱-黑胡椒提取物)
300mg L-α甘油基磷脂酰胆碱(GPC)
活性成分的mg水平为相当于每天4颗胶的每日剂量。例如，500mg南非醉茄等于125mg/份胶等。
实施例3
XrZice-疲劳缓解和能量增强
400-1000mg胶基
500mg瓜氨酸苹果酸
500mg L-酪氨酸
450mg(30ml)椰油粉
650mg喜来芝
400mg Guayusa
10mg胡椒素
活性成分的mg水平为相当于每天4粒胶的日剂量。例如，500mg的L-酪氨酸等于125mg/份胶等。
实施例4
XrZice 1-疲劳缓解和能量增强
400-1000mg胶基
500mg瓜氨酸苹果酸
300mgα甘油基磷脂酰胆碱
450mg(30ml)椰油粉
650mg喜来芝
400mg Guayusa
10mg胡椒素
活性成分的mg水平为相当于每天4粒胶的日剂量。例如，500mg的瓜氨酸苹果酸等于125mg/份胶等。
实施例5
增强精神清晰度和集中力的咀嚼胶的成分
400-1000mg胶基
300mg L-酪氨酸
200mg L-茶氨酸
150mg燕麦提取物(燕麦)
300mg磷脂酰丝氨酸
10mg维生素B6
350mg猫爪草根提取物(绒毛钩藤)
300mg(L-α甘油基磷脂酰胆碱(GPC)
350mg假马齿苋
500mg南非醉茄(Withania somnifera)
250mg狮鬃菇
300mg L-瓜氨酸
10mg长春西汀
10mg胡椒素(黑胡椒提取物)
100mg紫檀芪
300mg红景天
Mg水平为相当于每天4粒胶的日剂量。例如，500mg的南非醉茄等于125mg/份胶等。
实施例6
提供疲劳缓解和能量增强的咀嚼胶的成分
400-1000mg胶基
300mgα甘油基磷脂酰胆碱
500mg夏栎木提取物"QR"
450mg(30ml)椰油粉
650mg喜来芝
500mg Guayusa
10mg胡椒素
10mg长春西汀
10mg维生素B6
300mg CoQ10
400mg狮鬃菇
400mg灵芝
Mg水平为相当于每天4粒胶的日剂量。例如，500mg的"QR"等于125mg/份胶等。
实施例7
增强精神清晰度和集中力的咀嚼胶的成分
400-2500mg胶基
75mg喜来芝
62.5mg L-酪氨酸
43.75假马齿苋
31.25mg磷脂酰丝氨酸，无GMO
31.25mg甘油基磷脂酰胆碱
31.25mg南非醉茄
18.75mg辅酶Q10
2-5mg胡椒素(胡椒碱-黑胡椒提取物)
活性成分的mg水平为相当于每天4粒胶的日剂量。例如，300mg的喜来芝等于75mg/份胶等。
实施例8
增强精神清晰度和集中力的咀嚼胶的成分
400-2500mg胶基
75mg喜来芝
62.5mg L-酪氨酸
31.25mg南非醉茄
31.25mg L-α甘油基磷脂酰胆碱(GPC)
18.75mg辅酶Q10
12mg白藜芦醇
2mg维生素B6
2-5mg胡椒素(胡椒碱-黑胡椒提取物)
活性成分的mg水平为相当于每天4粒胶的日剂量。例如，300mg的喜来芝等于75mg/份胶等。
实施例9
XrZice2-疲劳缓解和能量增强
400-2500mg胶基
75mg喜来芝
37.5mg磷脂酰丝氨酸，无GMO
37.5mg甘油基磷脂酰胆碱
37.5mg刺五加
18.75mg辅酶Q10
2mg维生素B6
2-5mg胡椒素(胡椒碱-黑胡椒提取物)
活性成分的mg水平为相当于每天4粒胶的日剂量。例如，75mg的喜来芝等于300mg/份胶等。
实施例10
XrZice3-疲劳缓解和能量增强
400-2500mg胶基
75mg喜来芝
37.5mg磷脂酰丝氨酸，无GMO
37.5mg刺五加
37.5灵芝
37.5猴头
18.75mg辅酶Q10
12mg白藜芦醇
2mg维生素B6
2-5mg胡椒素(胡椒碱-黑胡椒提取物)
活性成分的mg水平为相当于每天4粒胶的日剂量。例如，300mg的喜来芝等于75mg/份胶等。
实施例11
增强精神清晰度和集中力的咀嚼胶的成分
400-2500mg胶基
62.5mg L-酪氨酸
43.75mg假马齿苋
31.25mg南非醉茄(Withania somnifera)
31.25mg磷脂酰丝氨酸
31.25mg猫爪草根提取物(绒毛钩藤)
31.25mg(L-α甘油基磷脂酰胆碱(GPC)
2mg维生素B6
2-5mg胡椒素(胡椒碱-黑胡椒提取物)
Mg水平为相当于每天4粒胶的日剂量。例如，125mg的南非醉茄等于31.25mg/份胶等。
实施例12
提供疲劳缓解和能量增强的咀嚼胶的成分
400-1000mg胶基
250mg喜来芝
100mg CoQ10
37.5mgα甘油基磷脂酰胆碱
37.5mg西伯利亚人参
2-5mg胡椒素(胡椒碱-黑胡椒提取物)
Mg水平为相当于每天4粒胶的日剂量。例如，250mg的喜来芝等于62.5mg/份胶等。
Claims (14)
1.一种包含胶基和活性成分的功能性咀嚼胶，所述活性成分增强精神清晰度和集中力，其中所述活性成分至少为喜来芝、南非醉茄、磷脂酰丝氨酸(优选地，无GMO)、L-α甘油基磷脂酰胆碱(α-GPC)和胡椒碱(即黑胡椒5提取物)。
2.如权利要求1所述的功能性咀嚼胶，其中其他活性成分选自：假马齿苋、L-酪氨酸、维生素B6、叶酸、猫爪草根提取物(绒毛钩藤)、L-瓜氨酸、白藜芦醇、叶酸、L-茶氨酸、长春西汀、维生素C、维生素B1、维生素B5、维生素B6和紫檀芪。
3.根据权利要求1或2所述的功能性咀嚼胶，其中所述其他活性成分是假马齿苋。
4.一种包含胶基和活性成分的功能性咀嚼胶，所述活性成分提供疲劳缓解和能量增强，其中所述活性成分至少为喜来芝、辅酶Q10、磷脂酰丝氨酸、西伯利亚人参和胡椒碱(黑胡椒提取物)。
5.如权利要求4所述的功能性咀嚼胶，其中其他活性成分选自：灵芝(Reishi)、维生素B6、甘油基磷脂酰胆碱、猴头菇(狮鬃菇)、锌、碘、镁、维生素B1、B2、B5、B6、B12。
6.根据权利要求4或5所述的功能性咀嚼胶，其中所述其他活性成分是甘油基磷脂酰胆碱。
7.一种包含胶基和活性成分的功能性咀嚼胶，所述活性成分增强精神清晰度和集中力，其中所述活性成分至少为南非醉茄、红景天、Guayusa、磷脂酰丝氨酸(优选地，无GMO)和胡椒碱(即黑胡椒提取物)。
8.如权利要求7所述的功能性咀嚼胶，其中其他活性成分选自：L-酪氨酸、L-茶氨酸、燕麦提取物(燕麦)、维生素B6、猫爪草根提取物(绒毛钩藤)、L-α甘油基磷脂酰胆碱(α-GPC)、假马齿苋、狮鬃菇、L-瓜氨酸、长春西汀和紫檀芪。
9.一种包含胶基和活性成分的功能性咀嚼胶，所述活性成分增强精神清晰度和集中力，其中所述活性成分至少为南非醉茄、红景天、L-茶氨酸、L-α甘油基磷脂酰胆碱(α-GPC)和胡椒碱(黑胡椒提取物)。
10.如权利要求9所述的功能性咀嚼胶，其中其他活性成分选自：L-酪氨酸、燕麦提取物(燕麦)、磷脂酰丝氨酸、维生素B6、猫爪草根提取物(绒毛钩藤)、Guayusa、假马齿苋、狮鬃菇、L-瓜氨酸、长春西汀、紫檀芪和磷脂酰丝氨酸(优选地，无GMO)。
11.一种包含胶基和活性成分的功能性咀嚼胶，所述活性成分提供疲劳缓解和能量增强，其中所述活性成分至少为瓜氨酸苹果酸、L-酪氨酸、椰油粉、喜来芝、Guayusa和胡椒碱(黑胡椒提取物)。
12.如权利要求11所述的功能性咀嚼胶，其中其他活性成分选自：α-甘油基磷脂酰胆碱、夏栎木提取物"QR"、长春西汀、维生素B6、CoQ10、狮鬃菇和灵芝。
13.一种包含胶基和活性成分的功能性咀嚼胶，所述活性成分提供疲劳缓解和能量增强，其中所述活性成分至少为瓜氨酸苹果酸、α-甘油基磷脂酰胆碱、椰油粉、喜来芝、Guayusa、胡椒碱(黑胡椒提取物)。
14.如权利要求11所述的功能性咀嚼胶，其中其他活性成分选自：L-酪氨酸、夏栎木提取物"QR"、长春西汀、维生素B6、CoQ10、狮鬃菇和灵芝。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20175763 | 2017-08-25 | ||
| FI20175763 | 2017-08-25 | ||
| PCT/EP2018/073039 WO2019038454A1 (en) | 2017-08-25 | 2018-08-27 | FUNCTIONAL CHEMICAL GUM COMPRISING PHYTONUTRIMENTS AND ADAPTOGENIC HERBS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111246847A true CN111246847A (zh) | 2020-06-05 |
Family
ID=63442617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880068554.1A Pending CN111246847A (zh) | 2017-08-25 | 2018-08-27 | 包含植物营养素和适应原草药的功能性咀嚼胶 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20200214978A1 (zh) |
| EP (1) | EP3672578A1 (zh) |
| CN (1) | CN111246847A (zh) |
| WO (1) | WO2019038454A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3095591B1 (fr) * | 2019-05-02 | 2021-11-19 | Fabre Pierre Dermo Cosmetique | Association d’un extrait de liane Uncaria tomentosa et d’un extrait de plantule d’avoine pour moduler les voies de la nociception |
| WO2023084508A1 (en) * | 2021-11-15 | 2023-05-19 | Zeevi Inon Moshe | Cognitive enhancing dietary supplement |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1121412A (zh) * | 1993-10-29 | 1996-05-01 | 卡迪列化学有限公司 | 含胡椒碱的组合物 |
| US8636985B2 (en) * | 2010-11-16 | 2014-01-28 | Jon Barron | Functional formulation in chewing gum |
| CN105031530A (zh) * | 2015-05-18 | 2015-11-11 | 简茗 | 一种抗衰老组合物 |
| US20160038552A1 (en) * | 2013-03-15 | 2016-02-11 | Buck Institute For Research On Aging | Improved cognitive supplements |
| CN109640703A (zh) * | 2016-08-04 | 2019-04-16 | 西雅图咖米公司 | 用于精神警觉的组合物及其制造和使用方法 |
-
2018
- 2018-08-27 US US16/641,707 patent/US20200214978A1/en not_active Abandoned
- 2018-08-27 CN CN201880068554.1A patent/CN111246847A/zh active Pending
- 2018-08-27 WO PCT/EP2018/073039 patent/WO2019038454A1/en unknown
- 2018-08-27 EP EP18762258.4A patent/EP3672578A1/en not_active Withdrawn
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1121412A (zh) * | 1993-10-29 | 1996-05-01 | 卡迪列化学有限公司 | 含胡椒碱的组合物 |
| US8636985B2 (en) * | 2010-11-16 | 2014-01-28 | Jon Barron | Functional formulation in chewing gum |
| US20160038552A1 (en) * | 2013-03-15 | 2016-02-11 | Buck Institute For Research On Aging | Improved cognitive supplements |
| CN105031530A (zh) * | 2015-05-18 | 2015-11-11 | 简茗 | 一种抗衰老组合物 |
| CN109640703A (zh) * | 2016-08-04 | 2019-04-16 | 西雅图咖米公司 | 用于精神警觉的组合物及其制造和使用方法 |
Non-Patent Citations (3)
| Title |
|---|
| 宋娜丽等: "胡椒碱的生物活性研究进展", 《云南中医中药杂志》 * |
| 郑建仙主编: "《功能性食品学》", 30 June 2009, 中国轻工业出版社 * |
| 阚凤玲等: "喜来芝：一种具有潜在促认知活性的植物复合物", 《腐殖酸》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019038454A1 (en) | 2019-02-28 |
| EP3672578A1 (en) | 2020-07-01 |
| US20200214978A1 (en) | 2020-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10517322B1 (en) | Dietary supplement formulations for promoting sleep | |
| KR100680121B1 (ko) | (리소-)포스파티딜세린을 포함하는 온혈동물에서 스트레스상태의 예방 및 치료용 제제 | |
| US10369182B2 (en) | Compositions and methods for treating insomnia and other sleep related disorders | |
| BR112016010422B1 (pt) | Suplemento dietético e método de tratamento para melhorar o desempenho ou energia física em um indivíduo | |
| WO2009079601A1 (en) | Methods and systems for sublingual guarana administration | |
| US20230115966A1 (en) | Paraxanthine-based bioactive composition and method of use thereof | |
| Rathee et al. | Natural memory boosters | |
| CN111246847A (zh) | 包含植物营养素和适应原草药的功能性咀嚼胶 | |
| CA3000494A1 (en) | Pharmaceutical compositions containing cannabis, uses thereof and methods for alleviating stress and/or anxiety | |
| US10500182B2 (en) | Compositions of ketogenic sources, micronutrients and phytochemicals for prophylaxis and mitigation of migraine headache | |
| WO2020115751A1 (en) | Cannabis-based compositions for the treatment of alzheimer's disease and dementia | |
| US20230125425A1 (en) | Traditional chinese medicine extract composition with function of regulating depressive emotion and preparation method and traditional chinese medicine preparation thereof | |
| US20220233617A1 (en) | Supplement for mitigating woman's disorders caused by ageing | |
| US10201577B2 (en) | Compositions and methods for enhancing working and long-term memory support using new combination of ginkgo biloba and panax ginseng and associated components | |
| TW201618802A (zh) | 用於調控ｐｐ２ａ甲基化反應並提供抗氧化及抗發炎活性之天然萃取物 | |
| JP2022133449A (ja) | レボドパ分割用量組成物および使用 | |
| US11311587B2 (en) | Pharmaceutical compositions containing cannabis, uses thereof and methods for improving energy levels and/or alleviating fatigue | |
| US11224589B2 (en) | Compositions for a dietary supplement to improve sleep | |
| RU2274400C1 (ru) | Биологически активная добавка для снижения алкогольной зависимости на основе расторопши пятнистой | |
| US20130280354A1 (en) | Composition and Method for Using Sage | |
| US20160367559A1 (en) | Time Released Caffeine | |
| US10568856B2 (en) | Composition for improved sleep | |
| EP4366730A1 (en) | Composition for promoting restful sleep and methods of making and using the same | |
| Mule et al. | CLINICAL UNDERSTANDING OF DIFFERENT LEHA KALPANA OF HARITAKI IE AGATSYA HARITAKI AVALEHA, KAMSA HARITAKI AVALEHA AND DANTI HARITAKI AVALEHA | |
| WO2024003560A1 (en) | Herbal composition for use in the improvement of physical and mental health recovery and maintenance, including the improvement of cognitive function or prevention of cognitive decline |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200605 |